New interim analysis study findings presented for the first time at the 55th American Society of Hematology (ASH) Annual Meeting in New Orleans suggest bendamustine and rituximab (BR) as a new treatment option for fit elderly patients with advanced Chronic Lymphocytic Leukaemia (CLL)
For European medical media: CLL10 Suggests Levact & Rituximab as New Treatment Option for Fit Elderly CLL Patients
Release Date: 09 Dec 2013